TY - JOUR
T1 - Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging
T2 - Revealing the Theranostic Potential of SSTR-and PSMA-Directed Endoradiotherapy
AU - Hasenauer, Natalie
AU - Higuchi, Takahiro
AU - Deschler-Baier, Barbara
AU - Hartrampf, Philipp E.
AU - Pomper, Martin G.
AU - Rowe, Steven P.
AU - Fassnacht, Martin
AU - Buck, Andreas K.
AU - Werner, Rudolf A.
N1 - Funding Information:
Conflicts of interest and sources of funding: The authors have no conflicts of interest to declare. This work was supported by the Okayama University “RECTOR” Program (T.H.).
Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.
AB - We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.
KW - endoradiotherapy
KW - medullary thyroid carcinoma
KW - PSMA
KW - radioligand therapy
KW - SSTR
KW - theranostics
UR - http://www.scopus.com/inward/record.url?scp=85131771180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131771180&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000004082
DO - 10.1097/RLU.0000000000004082
M3 - Article
C2 - 35085172
AN - SCOPUS:85131771180
SN - 0363-9762
VL - 47
SP - 651
EP - 652
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 7
ER -